See more : TCI Industries Limited (TCIIND.BO) Income Statement Analysis – Financial Results
Complete financial analysis of ANI Pharmaceuticals, Inc. (ANIP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ANI Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- National Grid plc (NG.L) Income Statement Analysis – Financial Results
- SEDCO Capital REIT Fund (4344.SR) Income Statement Analysis – Financial Results
- Great Harvest Maeta Holdings Limited (3683.HK) Income Statement Analysis – Financial Results
- Guangzhou Holike Creative Home Co.,Ltd. (603898.SS) Income Statement Analysis – Financial Results
- Huaibei GreenGold Industry Investment Co., Ltd. (2450.HK) Income Statement Analysis – Financial Results
ANI Pharmaceuticals, Inc. (ANIP)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.anipharmaceuticals.com
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 486.82M | 316.39M | 216.14M | 208.48M | 206.55M | 201.58M | 176.84M | 128.62M | 76.32M | 55.97M | 30.08M | 2.30M | 435.16K | 2.47M | 1.26M | 3.78M | 493.05K | 14.44M | 258.35K | 77.89K | 65.49K | 2.83M | 1.75M | 2.00 | 1.00 | 123.06K |
| Cost of Revenue | 181.51M | 138.79M | 100.61M | 87.16M | 63.15M | 73.02M | 79.03M | 48.78M | 12.69M | 11.47M | 9.97M | 9.17M | 50.00K | 268.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -24.29K | 0.00 | 0.00 |
| Gross Profit | 305.30M | 177.60M | 115.53M | 121.32M | 143.39M | 128.55M | 97.81M | 79.84M | 63.63M | 44.50M | 20.11M | -6.87M | 385.16K | 2.21M | 1.26M | 3.78M | 493.05K | 14.44M | 258.35K | 77.89K | 65.49K | 2.83M | 1.75M | 24.29K | 1.00 | 123.06K |
| Gross Profit Ratio | 62.71% | 56.13% | 53.45% | 58.19% | 69.42% | 63.77% | 55.31% | 62.07% | 83.37% | 79.50% | 66.84% | -298.44% | 88.51% | 89.14% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 1,214,600.00% | 100.00% | 100.00% |
| Research & Development | 34.29M | 22.32M | 11.37M | 16.00M | 19.81M | 15.39M | 9.07M | 2.91M | 2.87M | 2.68M | 1.71M | 16.89M | 44.18M | 39.71M | 13.68M | 15.79M | 4.75M | 3.86M | 6.41M | 9.16M | 3.69M | 4.79M | 2.14M | 1.89M | 660.59K | 1.40M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.06M | 31.58M | 27.83M | 21.16M | 17.94M | 16.39M | 8.23M | 6.98M | 5.94M | 5.67M | 5.96M | 4.33M | 7.03M | 3.05M | 3.08M | 2.33M | 1.77M | 2.30M | 1.68M | 853.39K | 1.11M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 161.70M | 124.04M | 84.29M | 64.99M | 55.84M | 44.06M | 31.58M | 27.83M | 21.16M | 17.94M | 16.39M | 8.23M | 6.98M | 5.94M | 5.67M | 5.96M | 4.33M | 7.03M | 3.05M | 3.08M | 2.33M | 1.77M | 2.30M | 1.68M | 853.39K | 1.11M |
| Other Expenses | 62.35M | 56.97M | 48.03M | 55.90M | 51.32M | -550.00K | 55.00K | -74.00K | 41.00K | 160.00K | -305.00K | 353.95K | 148.24K | 167.99K | 20.33M | 43.14K | 89.82K | 117.78K | 100.94K | 101.94K | 92.93K | 92.10K | 92.56K | 122.79K | 90.97K | 269.70K |
| Operating Expenses | 258.33M | 203.33M | 143.70M | 136.89M | 126.97M | 93.19M | 68.58M | 53.08M | 30.93M | 24.49M | 19.21M | 25.47M | 51.31M | 45.81M | 39.68M | 21.79M | 9.17M | 11.00M | 9.56M | 12.34M | 6.11M | 6.64M | 4.53M | 3.69M | 1.60M | 2.78M |
| Cost & Expenses | 439.85M | 342.12M | 244.31M | 224.05M | 190.12M | 166.22M | 147.61M | 101.86M | 43.62M | 35.96M | 29.18M | 25.47M | 51.36M | 46.08M | 39.68M | 21.79M | 9.17M | 11.00M | 9.56M | 12.34M | 6.11M | 6.64M | 4.53M | 3.66M | 1.60M | 2.78M |
| Interest Income | 0.00 | 28.05M | 11.92M | 9.45M | 12.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.54K | 8.33K | 12.67K | 11.65K | 588.46K | 1.10M | 428.34K | 401.19K | 250.42K | 86.59K | 63.79K | 174.42K | 227.72K | 0.00 | 0.00 |
| Interest Expense | 26.94M | 28.05M | 11.92M | 9.45M | 12.97M | 14.76M | 12.04M | 11.33M | 11.01M | 787.00K | 467.00K | 348.02K | 681.57K | 688.08K | 147.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 59.79M | 56.97M | 47.25M | 44.64M | 44.61M | 33.74M | 27.93M | 22.34M | 6.90M | 3.88M | 1.11M | 258.95K | 148.24K | 167.99K | 137.28K | 43.14K | 89.82K | 117.78K | 100.94K | 101.94K | 92.93K | 92.10K | 110.56K | 122.79K | 90.97K | 139.77K |
| EBITDA | 106.60M | 48.07M | -1.68M | 29.07M | 60.74M | 69.10M | 57.16M | 56.31M | 39.64M | 24.04M | 7.51M | -27.23M | -50.78M | -45.34M | -47.24M | -17.38M | -7.49M | 3.56M | -9.55M | -11.91M | -5.95M | -3.72M | -2.68M | -3.31M | -1.51M | -2.52M |
| EBITDA Ratio | 21.90% | 10.09% | 6.82% | 13.71% | 29.44% | 34.01% | 32.35% | 38.12% | 51.94% | 42.96% | 5.66% | -995.51% | -11,667.01% | -1,678.41% | -2,330.70% | -475.31% | -1,742.13% | 32.10% | -3,271.24% | -15,618.58% | -9,089.41% | -131.22% | -153.10% | -177,106,050.00% | -151,397,600.00% | -2,047.48% |
| Operating Income | 46.97M | -25.06M | -32.51M | -16.06M | 16.35M | 35.36M | 28.33M | 20.08M | 32.70M | 20.01M | 898.00K | -23.17M | -50.93M | -43.61M | -38.43M | -18.01M | -8.68M | 3.44M | -9.30M | -12.27M | -6.05M | -3.81M | -2.79M | -3.66M | -1.60M | -2.66M |
| Operating Income Ratio | 9.65% | -7.92% | -15.04% | -7.71% | 7.92% | 17.54% | 16.02% | 15.61% | 42.84% | 35.74% | 2.99% | -1,007.14% | -11,703.01% | -1,762.50% | -3,054.36% | -476.45% | -1,760.34% | 23.82% | -3,600.61% | -15,749.47% | -9,231.29% | -134.47% | -159.43% | -183,245,550.00% | -160,494,100.00% | -2,161.05% |
| Total Other Income/Expenses | -27.10M | -27.38M | -16.27M | -9.95M | -13.19M | -15.31M | -11.98M | -11.40M | -10.97M | -627.00K | -772.00K | -5.60M | -681.67K | -2.59M | -9.10M | -17.41B | -7.58B | -1.08M | -348.81K | 250.42K | 86.59K | 0.00 | 174.42K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 19.87M | -62.67M | -56.06M | -25.96M | 3.16M | 20.05M | 16.35M | 8.68M | 21.73M | 19.38M | 126.00K | -27.84M | -51.61B | -46.20B | -47.53B | -17.43B | -7.58B | 2.79B | -9.65B | -12.02M | -5.96M | -3.81M | -2.61M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 4.08% | -19.81% | -25.94% | -12.45% | 1.53% | 9.95% | 9.24% | 6.75% | 28.48% | 34.62% | 0.42% | -1,210.03% | -11,859,661.73% | -1,867,089.37% | -3,777,879.80% | -460,882.47% | -1,538,256.46% | 19,331.99% | -3,735,629.43% | -15,427.94% | -9,099.08% | -134.47% | -149.44% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.09M | -14.77M | -13.46M | -3.41M | -2.94M | 4.56M | 17.43M | 4.74M | 6.36M | -9.37M | 20.00K | -121.79K | 681.67K | 2.59M | 9.10M | -17.41B | -7.58B | 648.49K | 348.81K | 0.00 | 0.00 | 0.00 | 0.00 | -227.72K | -198.68K | 0.00 |
| Net Income | 18.78M | -47.90M | -42.60M | -22.55M | 6.09M | 15.49M | -1.08M | 3.93M | 15.38M | 28.75M | 301.00K | -27.72M | -51.61M | -46.20M | -47.53M | -17.43M | -7.58M | 2.79M | -9.65M | -12.02M | -5.96M | -3.81M | -2.61M | -3.44M | -1.41M | -2.66M |
| Net Income Ratio | 3.86% | -15.14% | -19.71% | -10.82% | 2.95% | 7.69% | -0.61% | 3.06% | 20.14% | 51.36% | 1.00% | -1,204.73% | -11,859.66% | -1,867.09% | -3,777.88% | -460.88% | -1,538.26% | 19.33% | -3,735.63% | -15,427.94% | -9,099.08% | -134.47% | -149.44% | -171,859,750.00% | -140,625,900.00% | -2,161.05% |
| EPS | 0.95 | -2.95 | -3.38 | -1.88 | 0.51 | 1.33 | -0.09 | 0.34 | 1.34 | 2.61 | -0.92 | -7.64 | -18.88 | -25.23 | -50.39 | -22.97 | -10.71 | 4.68 | -17.92 | -25.23 | -19.44 | -18.28 | -14.50 | -21.51 | -10.24 | -27.47 |
| EPS Diluted | 0.94 | -2.95 | -3.38 | -1.88 | 0.50 | 1.32 | -0.09 | 0.34 | 1.32 | 2.59 | -0.92 | -7.64 | -18.88 | -25.23 | -50.39 | -22.97 | -10.71 | 4.68 | -17.92 | -25.23 | -19.44 | -18.28 | -14.50 | -21.51 | -10.24 | -27.47 |
| Weighted Avg Shares Out | 18.00M | 16.26M | 12.60M | 11.96M | 11.84M | 11.68M | 11.55M | 11.45M | 11.37M | 10.94M | 5.07M | 3.63M | 2.73M | 1.83M | 943.11K | 758.54K | 707.93K | 588.64K | 538.67K | 476.26K | 306.63K | 208.42K | 180.15K | 159.82K | 137.29K | 96.83K |
| Weighted Avg Shares Out (Dil) | 18.19M | 16.26M | 12.60M | 11.96M | 12.04M | 11.77M | 11.55M | 11.57M | 11.56M | 11.05M | 5.07M | 3.63M | 2.73M | 1.83M | 943.11K | 758.54K | 707.93K | 596.78K | 538.67K | 476.26K | 306.63K | 208.42K | 180.15K | 159.82K | 137.29K | 96.83K |
ANI Pharmaceuticals to Participate at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
BAUDETTE, Minn., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology...
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP
BAUDETTE, Minn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg.
ANI Pharmaceuticals (ANIP) Beats Stock Market Upswing: What Investors Need to Know
In the most recent trading session, ANI Pharmaceuticals (ANIP) closed at $56.17, indicating a +1.37% shift from the previous trading day.
ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note
ANI Pharmaceuticals (ANIP) closed at $55.41 in the latest trading session, marking a -0.32% move from the prior day.
ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP
BAUDETTE, Minn., Jan. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Indomethacin Oral Suspension...
ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
BAUDETTE, Minn., Nov. 22, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President & CEO, will participate at the Piper Sandler 35th Annual Healthcare Conference in New York City as...
ANI Pharmaceuticals, Inc. (ANIP) Q3 2023 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Judy DiClemente - Insight Communications IR Nikhil Lalwani - President and CEO Stephen Carey - CFO Conference Call Participants Les Sulewski -...
Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates...
ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
Third Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3% ; net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45 -- -- Record quarterly...
3 Catalysts Could Drive ANI Pharmaceuticals' PPS Growth Through November 2023
ANIP's PPS has gained 63.41% YTD and is expected to continue growing. ANIP should record its fifth consecutive quarter beating earnings and revenue consensus. ANIP's Sovuna, a unique version of Hydroxychloroquine sulfate, and a new 1-ml vial version of Purified...
Source: https://incomestatements.info
Category: Stock Reports